WEBULL
News
IONS
79.98
+0.06%
0.05
Cathie Wood invests heavily in gene-editing companies, offloads $30 million worth Tesla stock
Seeking Alpha · 14h ago
Weekly Report: what happened at IONS last week (1222-1226)?
Weekly Report · 17h ago
Weekly Report: what happened at IONS last week (1215-1219)?
Weekly Report · 12/22 09:26
Will FDA Approval of Tryngolza and Analyst Support Change Ionis Pharmaceuticals' (IONS) Narrative?
Simply Wall St · 12/22 05:17
IONS, IBTA, IRDM: Cathie Wood Continues Trimming Stakes in Ionis, Ibotta, and Iridium Stocks
TipRanks · 12/22 03:37
Ionis Pharmaceuticals (IONS): Revisiting Valuation After a Powerful Year-to-Date Share Price Rally
Simply Wall St · 12/19 04:49
Ionis Pharmaceuticals Is Maintained at Outperform by RBC Capital
Dow Jones · 12/17 15:12
RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $95
Benzinga · 12/17 15:02
Ionis Pharmaceuticals price target raised to $95 from $82 at RBC Capital
TipRanks · 12/17 13:12
Arrowhead price target raised to $100 from $70 at Piper Sandler
TipRanks · 12/17 11:50
RBC Capital Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)
TipRanks · 12/17 11:48
Is It Too Late to Consider Ionis After Its 126% Surge in 2025?
Simply Wall St · 12/17 05:21
Ionis Pharmaceuticals Is Maintained at Outperform by Leerink Partners
Dow Jones · 12/15 20:55
Ionis Pharmaceuticals Price Target Raised to $100.00/Share From $85.00 by Leerink Partners
Dow Jones · 12/15 20:55
Leerink Partners Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $100
Benzinga · 12/15 20:45
Leerink Partners Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)
TipRanks · 12/15 14:35
Ionis Pharmaceuticals price target raised to $100 from $85 at Leerink
TipRanks · 12/15 14:21
IONIS PHARMACEUTICALS INC <IONS.O>: LEERINK PARTNERS RAISES TARGET PRICE TO $100 FROM $85
Reuters · 12/15 11:59
Weekly Report: what happened at IONS last week (1208-1212)?
Weekly Report · 12/15 09:28
Alnylam Pharmaceuticals: Challenges In The TTR Space And Few Late-Stage Catalysts Are A Concern
Seeking Alpha · 12/14 03:45
More
Webull provides a variety of real-time IONS stock news. You can receive the latest news about Ionis Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.